The gut microbiome in Parkinson’s disease: longitudinal insights into disease progression and the use of device-assisted therapies.
Objective: We investigated the temporal stability of gut microbiome (GM) profiles from Parkinson’s disease (PD) patients initiating device-assisted therapies (DAT) and in a separate cohort…Gut microbiota and nutritional profiles of Parkinson’s disease patients.
Objective: We investigated the gut microbiome (GM) composition in association with various clinical features and nutritional data in a large cross-sectional Australian Parkinson’s disease (PD)…PD phenotype with premotor RBD is associated with a dysbiotic profile of gut microbiota.
Objective: The aim of the study was to compare the fecal microbial composition of a group of PD patients with and without premotor RBD. Background:…Dystonic tremor and ataxia as presenting symptoms of multiple sclerosis
Objective: Introduction Tremor in multiple sclerosis (MS) has traditionally been thought to be a feature of advanced disease and pathophysiology of MS tremor is known…The Role Imposed by The High-Mobility Group Box 1 (HMGB1) Protein in MPTP-Induced Zebrafish Model of Parkinson’s Disease
Objective: This study aims to investigate the role of HMGB1 protein in mediating neuroinflammatory-induced parkinsonian movement disorder of the MPTP-induced zebrafish model of Parkinson's disease…TNF-α Mediated Neuroinflammation Associated with UPRmt in Kaolin Induced Hydrocephalus Mouse Model
Objective: To identify the association between tumor necrosis factor-α (TNF-α) signaling and mitochondrial unfolded protein responses (UPRmt) against ventricular expansion, we used the kaolin induced…Progression of neuroinflammation in patients with isolated REM sleep behavior disorder. A 11C-PK11195 PET study
Objective: The aim of this study was to investigate in vivo the progression of neuroinflammation iRBD patients over a 3-year follow-up. Background: Isolated rapid-eye-movement behaviour…Effect of probiotics on MDS UPDRS in Parkinson disease at 12 weeks: A Randomized double-blind placebo-controlled trial
Objective: The primary objective was to find the effect of 12 weeks of probiotic supplementation on MDS UPDRS score in Parkinson’s Disease. The secondary objectives…Fecal Calprotectin in Parkinson’s Disease and Multiple System Atrophy
Objective: To investigate the levels of fecal calprotectin (a marker of intestinal inflammation), in patients with Parkinson's Disease (PD) and multiple system atrophy (MSA) compared…Safety and Tolerability of a Ketone Supplement in Parkinson’s Disease
Objective: To investigate the safety and tolerability of a high-dose exogenous ketone supplement in people with Parkinson’s Disease (PD). Background: Animal models and small pilot…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 25
- Next Page »